Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1373073rdf:typepubmed:Citationlld:pubmed
pubmed-article:1373073lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:1373073lifeskim:mentionsumls-concept:C0040300lld:lifeskim
pubmed-article:1373073lifeskim:mentionsumls-concept:C0033572lld:lifeskim
pubmed-article:1373073lifeskim:mentionsumls-concept:C0002844lld:lifeskim
pubmed-article:1373073lifeskim:mentionsumls-concept:C1704272lld:lifeskim
pubmed-article:1373073lifeskim:mentionsumls-concept:C0056855lld:lifeskim
pubmed-article:1373073lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1373073pubmed:issue1lld:pubmed
pubmed-article:1373073pubmed:dateCreated1992-5-12lld:pubmed
pubmed-article:1373073pubmed:abstractTextTestosterone, 5 alpha-dihydrotestosterone and cyproterone acetate (CPA) were estimated in samples of prostate tissue, obtained from benign prostatic hyperplasia (BPH) patients who were or were not pretreated with CPA. Furthermore, these steroids were estimated in various fractions of the BPH tissue, and the number of nuclear androgen-receptor sites was determined. CPA-treatment caused a 4-fold, significant suppression of 5 alpha-dihydrotestosterone levels in total prostate tissue and its subfractions, without affecting testosterone levels or the androgen-receptor contents of the nuclear extracts. Nuclear concentrations of CPA were twice as high as those of 5 alpha-dihydrotestosterone. It is concluded that effects of CPA may have been caused through a combination of the following mechanisms: (1) suppression of peripheral androgen levels; (2) competition with androgens for (nuclear) androgen-receptors; and (3) suppression of prostatic 5 alpha-reductase.lld:pubmed
pubmed-article:1373073pubmed:languageenglld:pubmed
pubmed-article:1373073pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1373073pubmed:citationSubsetIMlld:pubmed
pubmed-article:1373073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1373073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1373073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1373073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1373073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1373073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1373073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1373073pubmed:statusMEDLINElld:pubmed
pubmed-article:1373073pubmed:monthMarlld:pubmed
pubmed-article:1373073pubmed:issn0960-0760lld:pubmed
pubmed-article:1373073pubmed:authorpubmed-author:de JongF HFHlld:pubmed
pubmed-article:1373073pubmed:authorpubmed-author:SchroederF...lld:pubmed
pubmed-article:1373073pubmed:authorpubmed-author:MulderEElld:pubmed
pubmed-article:1373073pubmed:authorpubmed-author:BlomJ HJHlld:pubmed
pubmed-article:1373073pubmed:authorpubmed-author:Bolt-de...lld:pubmed
pubmed-article:1373073pubmed:authorpubmed-author:ReuversP JPJlld:pubmed
pubmed-article:1373073pubmed:issnTypePrintlld:pubmed
pubmed-article:1373073pubmed:volume42lld:pubmed
pubmed-article:1373073pubmed:ownerNLMlld:pubmed
pubmed-article:1373073pubmed:authorsCompleteYlld:pubmed
pubmed-article:1373073pubmed:pagination49-55lld:pubmed
pubmed-article:1373073pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:meshHeadingpubmed-meshheading:1373073-...lld:pubmed
pubmed-article:1373073pubmed:year1992lld:pubmed
pubmed-article:1373073pubmed:articleTitleAndrogens and androgen-receptors in prostate tissue from patients with benign prostatic hyperplasia: effects of cyproterone acetate.lld:pubmed
pubmed-article:1373073pubmed:affiliationDepartment of Endocrinology and Reproduction, Erasmus University Rotterdam, The Netherlands.lld:pubmed
pubmed-article:1373073pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1373073pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed